Dr. Howard Smith Oncall

Vidcast:   https://www.instagram.com/p/DNd6KltPeD_/Transplantation immuno-geneticists at Sweden’s Uppsala University Hospital have successfully used gene editing to modify human pancreatic islet cells such that these transplants are more histocompatible, survive longer, and function better.  Their single patient case report appeared in a recent issues of the New England Journal of Medicine.The recipient is a 42-year-old male juvenile-onset insulin-dependent diabetic. The researchers utilized CRISPR-Cas12b gene editing technology to delete genes that code for incompatible cell surface antigens while adding genes coding for protective antigens thereby making the donor pancreatic cells invisible to the recipient’s immune system.Over a 12-week period, the limited number of gene-edited islet cells available for transplantation were able to reduce but not totally eliminate the recipients insulin requirement.  This proved the viability and functional integrity of the transplanted islet cells suggesting that transpla